Cytokinetics (NASDAQ:CYTK – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cytokinetics and AbCellera Biologics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytokinetics | 1 | 1 | 19 | 0 | 2.86 |
| AbCellera Biologics | 1 | 1 | 8 | 2 | 2.92 |
Cytokinetics currently has a consensus target price of $106.67, suggesting a potential upside of 100.61%. AbCellera Biologics has a consensus target price of $16.55, suggesting a potential upside of 48.79%. Given Cytokinetics’ higher possible upside, equities analysts clearly believe Cytokinetics is more favorable than AbCellera Biologics.
Earnings & Valuation
This table compares Cytokinetics and AbCellera Biologics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cytokinetics | $113.29 million | 65.38 | -$784.96 million | ($6.04) | -8.80 |
| AbCellera Biologics | $67.85 million | 53.53 | -$146.41 million | ($0.48) | -23.17 |
AbCellera Biologics has lower revenue, but higher earnings than Cytokinetics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Cytokinetics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Institutional and Insider Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Cytokinetics and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytokinetics | -686.63% | N/A | -48.26% |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
Summary
AbCellera Biologics beats Cytokinetics on 9 of the 15 factors compared between the two stocks.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
